Diagnostic accuracy of OCTA and OCT for myopic choroidal neovascularisation: a systematic review and meta-analysis

Abstract

Learning ObjectivesUpon completion of this activity, participants will be able to:Describe test accuracy, pooled sensitivity and pooled specificity of optical coherence tomography angiography (OCTA) and spectral domain (SD)-OCT in diagnosing myopic choroidal neovascularization (mCNV) compared with fluorescein angiography (FA) as the reference standard, according to a meta-analysis.Determine clinical recommendations for using OCTA and SD-OCT in diagnosing mCNV, according to a meta-analysis.Identify other clinical and research implications of test accuracy, pooled sensitivity and pooled specificity of OCTA and SD-OCT in diagnosing mCNV compared with FA as the reference standard, according to a meta-analysis.Accreditation StatementsIn support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eye; (4) view/print certificate.Credit hours1.0Release date:Expiration date:Post-test link:https://medscape.org/eye/posttest978466Journal CME author disclosure informationLaurie Barclay, MD Freelance writer and reviewer, Medscape, LLC, and has disclosed the following relevant financial relationships: formerly owned stocks in AbbVie.